nach oben

Erschienen in:

21.12.2015 | Original Research Article

Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection

verfasst von: Andreas Krause, Jochen Zisowsky, Daniel S. Strasser, Martine Gehin, Patricia N. Sidharta, Peter M. A. Groenen, Jasper Dingemanse

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

The chemoattractant receptor-homologous molecule expressed on T helper-2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D₂ (PGD₂), a key mediator in inflammatory disorders. Two selective and potent CRTH2 antagonists currently in clinical development, ACT-453859 and setipiprant, were compared with respect to their (predicted) clinical efficacy.

Methods

Population pharmacokinetic (PK) and pharmacodynamic (PD) models were developed to characterize how plasma concentrations (PK) of ACT-453859, its active metabolite ACT-463036 and setipiprant related to their effect on blocking PGD₂-induced internalization of CRTH2 on eosinophils (PD). Simulations were used to identify doses and dosing regimens leading to 90 % of maximum blockade of CRTH2 internalization at trough.

Results

A combined concentration of ACT-453859 and its metabolite ACT-463036, with weights proportional to potency (based on an eosinophil shape change assay), enabled good characterization of the PD effect. The modelling and simulation results facilitated decision making by suggesting an ACT-453859 dose of 400 mg once daily (or 100 mg twice daily) for clinically relevant CRTH2 antagonism.

Conclusion

Pharmacometric quantification demonstrated that CRTH2 internalization is a useful new biomarker to study CRTH2 antagonism. Ninety percent of maximum blockade of CRTH2 internalization at trough is suggested as a quantitative PD target in clinical studies.

Nur mit Berechtigung zugänglich

Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999;459(2):195–9.CrossRefPubMed

Murray JJ, Tonnel AB, Brash AR, Roberts LJ 2nd, Gosset P, Workman R, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986;315(13):800–4. doi:10.1056/NEJM198609253151304.CrossRefPubMed

Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008;153(Suppl 1):S191–9. doi:10.1038/sj.bjp.0707488.PubMed

Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol. 2011;186(3):1861–9. doi:10.4049/jimmunol.1002568.CrossRefPubMed

Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov. 2007;6(4):313–25. doi:10.1038/nrd2266.CrossRefPubMed

Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–61. doi:10.1067/mai.2001.119917.CrossRefPubMed

Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001;108(6):982–8. doi:10.1067/mai.2001.119919.CrossRefPubMed

Robinson DS. Th-2 cytokines in allergic disease. Br Med Bull. 2000;56(4):956–68.CrossRefPubMed

Tanaka K, Hirai H, Takano S, Nakamura M, Nagata K. Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun. 2004;316(4):1009–14. doi:10.1016/j.bbrc.2004.02.151.CrossRefPubMed

10.

Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175(10):6531–6.CrossRefPubMed

11.

Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med. 2006;12(4):148–58. doi:10.1016/j.molmed.2006.02.005.CrossRefPubMed

12.

Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014;28(6):690–9. doi:10.1111/fcp.12079.CrossRefPubMed

13.

Diamant Z, Sidharta PN, Singh D, O’Connor BJ, Zuiker R, Leaker BR, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44(8):1044–52. doi:10.1111/cea.12357.CrossRefPubMed

14.

Gehin M, Strasser DS, Zisowsky J, Farine H, Groenen PM, Dingemanse J, et al. A novel CRTH2 antagonist: single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects. J Clin Pharmacol. 2015;77(7):787–97. doi:10.1002/jcph.478.CrossRef

15.

Strasser DS, Farine H, Holdener M, Zisowsky J, Roscher R, Hoerner J, et al. Development of a decision-making biomarker for CRTH2 antagonism in clinical studies. N Horiz Transl Med. 2015;2(4–5):118–25. doi:10.1016/j.nhtm.2015.05.001.

16.

Baldoni D, Mackie A, Gutierrez M, Theodor R, Dingemanse J. Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects. Clin Ther. 2013;35(11):1842–8. doi:10.1016/j.clinthera.2013.09.003.CrossRefPubMed

17.

R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.

18.

Lixoft-Incuballiance. Monolix user guide. Edition 4.2.0. Orsay: Lixoft-Incuballiance; 2012.

19.

Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69(9):1223–32. doi:10.1111/all.12451.CrossRefPubMed

20.

Actelion. Study of ACT-129968 in adult patients with seasonal allergic rhinitis (SAR). http://www.ClinicalTrials.gov. 2012. https://clinicaltrials.gov/show/NCT01241214. Accessed 15 Nov 2015.

21.

Bell S, Anderson L, Nugent C, Klopfenstein N, Eberhardt C, Carter L et al. Safety, PK and PD of ARRY-502, a CRTh2 antagonist, in healthy subjects with a history of seasonal allergies [abstract no. E3954]. European Respiratory Society Annual Congress; Barcelona; 18–22 Sep 2010.

22.

Thomas J, Gorski K, Evangelista C, Belouski SS, Banfield C, Ferbas J. Development and implementation of a CRTH2 receptor internalization assay for assessment of target coverage by a small molecule CRTH2/DP receptor antagonist [abstract no. T.94]. 11th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS); Washington, DC; 23–26 Jun 2011.

Titel: Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection
verfasst von: Andreas Krause
Jochen Zisowsky
Daniel S. Strasser
Martine Gehin
Patricia N. Sidharta
Peter M. A. Groenen
Jasper Dingemanse
Publikationsdatum: 21.12.2015
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 7/2016
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-015-0354-3

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen

Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers

Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations

Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels

Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome

Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations